{"entity":{"type":"insider","cik":"0001615856","url":"/insider/0001615856","json_url":"/insider/0001615856.json","name":"Gottesdiener Keith Michael","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":11,"first":"2018-04-09","last":"2019-03-19","span_basis":"filed_date"},"name_variants":[{"name":"Gottesdiener Keith Michael","source":"filing","n_filings":11,"first_seen":"2018-04-09","last_seen":"2019-03-19"}],"transactions":[{"id":8613865,"accession":"0001104659-19-015985","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-015985","line_url":"/filing/0001104659-19-015985#line-2","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO & President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2329.0,"shares_display":"2,329","price_per_share":30.27,"price_display":"30.27","price_state":"stated","total_value":70498.83,"total_display":"70,498.83","total_whole":"70,499","shares_owned_after":506342.0,"shares_owned_after_display":"506,342","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-19","scope":"insider"},{"id":8613862,"accession":"0001104659-19-015985","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-015985","line_url":"/filing/0001104659-19-015985#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO & President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7961.0,"shares_display":"7,961","price_per_share":30.04,"price_display":"30.04","price_state":"stated","total_value":239148.44,"total_display":"239,148.44","total_whole":"239,148","shares_owned_after":508671.0,"shares_owned_after_display":"508,671","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-15","filed_date":"2019-03-19","scope":"insider"},{"id":7912594,"accession":"0001104659-19-015281","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-015281","line_url":"/filing/0001104659-19-015281#line-2","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO & President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1506.0,"shares_display":"1,506","price_per_share":30.05,"price_display":"30.05","price_state":"stated","total_value":45255.3,"total_display":"45,255.30","total_whole":"45,255","shares_owned_after":516632.0,"shares_owned_after_display":"516,632","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-14","filed_date":"2019-03-15","scope":"insider"},{"id":7912590,"accession":"0001104659-19-015281","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-015281","line_url":"/filing/0001104659-19-015281#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO & President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7782.0,"shares_display":"7,782","price_per_share":30.06,"price_display":"30.06","price_state":"stated","total_value":233926.92,"total_display":"233,926.92","total_whole":"233,927","shares_owned_after":518138.0,"shares_owned_after_display":"518,138","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-13","filed_date":"2019-03-15","scope":"insider"},{"id":8053596,"accession":"0001104659-19-011530","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-011530","line_url":"/filing/0001104659-19-011530#line-2","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1814.0,"shares_display":"1,814","price_per_share":30.01,"price_display":"30.01","price_state":"stated","total_value":54438.14,"total_display":"54,438.14","total_whole":"54,438","shares_owned_after":525617.0,"shares_owned_after_display":"525,617","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-27","filed_date":"2019-02-28","scope":"insider"},{"id":8053594,"accession":"0001104659-19-011530","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-011530","line_url":"/filing/0001104659-19-011530#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":635.0,"shares_display":"635","price_per_share":30.13,"price_display":"30.13","price_state":"stated","total_value":19132.55,"total_display":"19,132.55","total_whole":"19,133","shares_owned_after":527431.0,"shares_owned_after_display":"527,431","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-26","filed_date":"2019-02-28","scope":"insider"},{"id":8237297,"accession":"0001104659-19-009555","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-009555","line_url":"/filing/0001104659-19-009555#line-2","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":918.0,"shares_display":"918","price_per_share":30.05,"price_display":"30.05","price_state":"stated","total_value":27585.9,"total_display":"27,585.90","total_whole":"27,586","shares_owned_after":528066.0,"shares_owned_after_display":"528,066","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-20","scope":"insider"},{"id":8237294,"accession":"0001104659-19-009555","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-009555","line_url":"/filing/0001104659-19-009555#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12002.0,"shares_display":"12,002","price_per_share":30.02,"price_display":"30.02","price_state":"stated","total_value":360300.04,"total_display":"360,300.04","total_whole":"360,300","shares_owned_after":528984.0,"shares_owned_after_display":"528,984","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-15","filed_date":"2019-02-20","scope":"insider"},{"id":8726701,"accession":"0001104659-19-009043","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-009043","line_url":"/filing/0001104659-19-009043#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3934.0,"shares_display":"3,934","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":118020.0,"total_display":"118,020.00","total_whole":"118,020","shares_owned_after":540986.0,"shares_owned_after_display":"540,986","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-13","filed_date":"2019-02-15","scope":"insider"},{"id":8145612,"accession":"0001104659-19-003144","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-003144","line_url":"/filing/0001104659-19-003144#line-2","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":105.0,"shares_display":"105","price_per_share":30.21,"price_display":"30.21","price_state":"stated","total_value":3172.05,"total_display":"3,172.05","total_whole":"3,172","shares_owned_after":544920.0,"shares_owned_after_display":"544,920","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-23","filed_date":"2019-01-24","scope":"insider"},{"id":8145608,"accession":"0001104659-19-003144","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-003144","line_url":"/filing/0001104659-19-003144#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15674.0,"shares_display":"15,674","price_per_share":30.05,"price_display":"30.05","price_state":"stated","total_value":471003.7,"total_display":"471,003.70","total_whole":"471,004","shares_owned_after":545025.0,"shares_owned_after_display":"545,025","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-22","filed_date":"2019-01-24","scope":"insider"},{"id":8145603,"accession":"0001104659-19-002735","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-002735","line_url":"/filing/0001104659-19-002735#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO & President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10115.0,"shares_display":"10,115","price_per_share":30.01,"price_display":"30.01","price_state":"stated","total_value":303551.15,"total_display":"303,551.15","total_whole":"303,551","shares_owned_after":560699.0,"shares_owned_after_display":"560,699","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-18","filed_date":"2019-01-22","scope":"insider"},{"id":7969692,"accession":"0001104659-19-002328","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-002328","line_url":"/filing/0001104659-19-002328#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO & President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":662.0,"shares_display":"662","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":19860.0,"total_display":"19,860.00","total_whole":"19,860","shares_owned_after":570814.0,"shares_owned_after_display":"570,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-16","filed_date":"2019-01-17","scope":"insider"},{"id":6117152,"accession":"0001104659-18-071680","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-071680","line_url":"/filing/0001104659-18-071680#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":563.0,"shares_display":"563","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":16890.0,"total_display":"16,890.00","total_whole":"16,890","shares_owned_after":571476.0,"shares_owned_after_display":"571,476","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-03","filed_date":"2018-12-06","scope":"insider"},{"id":6221258,"accession":"0001104659-18-066382","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-066382","line_url":"/filing/0001104659-18-066382#line-1","is_derivative":false,"issuer_cik":"0001615856","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","issuer_ticker":"RYTM","issuer_name_source":null,"issuer_url":"/issuer/0001615856","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16500.0,"shares_display":"16,500","price_per_share":30.08,"price_display":"30.08","price_state":"stated","total_value":496320.0,"total_display":"496,320.00","total_whole":"496,320","shares_owned_after":572039.0,"shares_owned_after_display":"572,039","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-02","filed_date":"2018-11-06","scope":"insider"},{"id":6490057,"accession":"0001144204-18-019837","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-18-019837","line_url":"/filing/0001144204-18-019837#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001615856","owner_name":"Gottesdiener Keith Michael","owner_display_name":"Gottesdiener Keith Michael","owner_url":"/insider/0001615856","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1171.0,"shares_display":"1,171","price_per_share":64.0,"price_display":"64.00","price_state":"stated","total_value":74944.0,"total_display":"74,944.00","total_whole":"74,944","shares_owned_after":5001.0,"shares_owned_after_display":"5,001","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-09","filed_date":"2018-04-09","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":16,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":15,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":16},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001649904","name":"RHYTHM PHARMACEUTICALS, INC.","url":"/issuer/0001649904","role":"Director, Officer (CEO & President)","n_filings":10,"first_seen":"2018-11-06","last_seen":"2019-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001270073","name":"INTERCEPT PHARMACEUTICALS INC","url":"/issuer/0001270073","role":"Director","n_filings":1,"first_seen":"2018-04-09","last_seen":"2018-04-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001615856","retrieved_at":"2026-08-26T09:28:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}